North America Pen Needles Market Research Report – Segmented By Therapy (Insulin Therapy, GLP-1 Therapy, Growth Hormone Therapy), Type, Needle Length, Mode Of Purchase & Country (The United States, Canada, Mexico and Rest of North America) - Industry Analysis From 2026 to 2034
Market Size, 2025
$0.95 BnMarket Estimate, 2026
$1.05 BnMarket Forecast, 2034
$2.35 BnCAGR, 2026–2034
10.60%The North America Pen needles market size was valued at USD 0.95 billion in 2025. The Pen needles market in North America is expected to reach USD 2.35 billion by 2034 from USD 1.05 billion in 2026, growing at a CAGR of 10.60% from 2026 to 2034.
Pen needles are small, disposable medical devices used in conjunction with insulin pens to administer precise doses of insulin for diabetes management. These needles come in various lengths and gauges, designed to ensure accurate subcutaneous delivery while minimizing pain and discomfort. In North America, the use of pen needles has gained significant traction due to the rising prevalence of diabetes, increased patient preference for self-administration, and advancements in needle technology.
The North American market is primarily driven by the United States, where diabetes affects over 37 million people as reported by the Centers for Disease Control and Prevention (CDC) in 2024. Canada also contributes substantially, with a growing geriatric population and increasing adoption of modern diabetes care solutions.
One of the most significant drivers of the North America Pen Needles Market is the escalating incidence of diabetes, particularly Type 1 and insulin-requiring Type 2 diabetes. This growing patient base directly translates into increased demand for insulin delivery systems, including pen needles. Insulin pens offer greater convenience, dosing accuracy, and portability compared to traditional vial and syringe methods, making them the preferred choice among patients and healthcare providers alike. Moreover, public health initiatives such as the CDC’s National Diabetes Prevention Program and Health Canada’s Diabetes Strategy aim to improve disease management through early intervention and better access to essential supplies.
Another key factor propelling the North America Pen Needles Market is the continuous innovation in needle design and manufacturing aimed at improving user experience and clinical outcomes. Manufacturers are increasingly investing in ultra-thin, short-length needles, silicone-coated surfaces, and safety-engineered models to reduce pain, minimize tissue trauma, and prevent needle-stick injuries.
For instance, BD (Becton, Dickinson and Company) introduced its Ultra-Fine™ Nano 32G needle in 2023, one of the thinnest insulin pen needles available on the market. Clinical studies cited by the company indicate that these needles can significantly enhance patient adherence by reducing injection-related discomfort. Similarly, Novo Nordisk launched the FlexTouch® compatible pen needle, featuring an auto-priming mechanism that simplifies dosing for elderly and visually impaired patients. According to the Journal of Diabetes Science and Technology, patient satisfaction scores improved by up to 30% with newer generation pen needles by encouraging wider adoption among both prescribers and end-users. Additionally, regulatory bodies like the U.S. Food and Drug Administration (FDA) are encouraging safer injection practices, which further supports the integration of advanced needle technologies into mainstream diabetes care. These innovations not only address long-standing patient concerns but also contribute to the expanding footprint of pen needles in North America.
Despite their benefits, the high cost of premium pen needles remains a notable restraint in the North America Pen Needles Market. While standard needles typically range between $0.10 and $0.30 per unit, advanced versions with features like micro-thinning, reduced length, and anti-backflow mechanisms can cost up to $0.50 per unit or more. For patients requiring multiple daily injections, this leads to a significant financial burden.
Insurance coverage for pen needles varies widely across the U.S., with many private plans offering limited reimbursement or imposing restrictive formulary policies. In some cases, patients opt for reuse of disposable needles an unsafe practice linked to infections and skin complications.
In Canada, although provincial healthcare programs provide partial coverage, supply shortages and administrative delays often hinder timely access. These economic and logistical barriers continue to impede widespread adoption, limiting market expansion despite strong underlying demand.
Stringent regulatory oversight presents another major challenge for manufacturers operating in the North America Pen Needles Market. Both the U.S. Food and Drug Administration (FDA) and Health Canada impose rigorous standards related to device approval, sterility assurance, labeling, and post-market surveillance. While these regulations ensure product safety, they also extend development timelines and increase compliance costs, particularly for smaller firms. For example, under FDA’s 21 CFR Part 820 guidelines, manufacturers must adhere to comprehensive quality system requirements, including validation of sterilization processes and traceability of raw materials. Additionally, recent changes in federal procurement policies have placed greater emphasis on domestic sourcing and environmental sustainability, compelling companies to restructure their supply chains. Health Canada’s Safe Injection Practices initiative has also mandated the inclusion of sharps injury protection features in all newly registered pen needles, further raising entry barriers for new players. These regulatory complexities slow down product launches and limit competitive diversity, constraining overall market dynamism.
A major opportunity emerging in the North America Pen Needles Market is the increasing integration of pen needles with smart insulin pens and digital health platforms. As diabetes management becomes more data-driven, pharmaceutical and medical device companies are developing connected pens that track dosage history, monitor adherence, and sync with mobile apps to provide real-time feedback. This trend is being fueled by partnerships between pen needle manufacturers and digital health firms aiming to enhance patient engagement and improve glycemic control.
For example, in 2023, Eli Lilly partnered with Gvoke to launch a Bluetooth-enabled insulin pen that records each injection and transmits data to a companion app. Such innovations require specialized pen needles that maintain compatibility with electronic components while ensuring seamless flow dynamics.
The rapid expansion of telemedicine and home healthcare services in North America is creating new avenues for growth in the Pen Needles Market. According to a 2024 report by McKinsey & Company, telehealth utilization in the U.S. remains 38 times higher than pre-pandemic levels, with diabetes management being one of the top conditions addressed through virtual consultations. This evolution supports the use of easy-to-use, portable insulin delivery systems such as pen needles, particularly among elderly and mobility-limited patients. Home healthcare agencies are increasingly incorporating pen needles into care packages provided to diabetic patients, ensuring continuity of treatment outside clinical settings. The Visiting Nurse Associations of America (VNAA) noted in 2023 that over 60% of home health nurses recommend pen needles over traditional syringes due to their ease of use and reduced risk of dosing errors. Furthermore, insurance providers and Medicaid programs are incentivizing home-based diabetes care to reduce hospital readmissions and lower overall healthcare costs.
One of the primary challenges facing the North America Pen Needles Market is the growing popularity of alternative insulin delivery methods, such as inhalable insulin, insulin pumps, and continuous glucose monitoring (CGM)-integrated systems. These technologies offer enhanced convenience, precision, and automation, appealing to both patients and healthcare providers seeking innovative diabetes management solutions. According to a 2024 report by Evaluate Pharma, insulin pump usage in the U.S. has increased by 12% annually over the past five years among pediatric and Type 1 diabetes patients. Insulin pumps eliminate the need for repeated needle insertions, thereby reducing injection fatigue and improving patient comfort. Companies like Medtronic and Dexcom have further strengthened this segment through the integration of automated insulin delivery (AID) systems. Additionally, inhalable insulin products such as Afrezza, developed by MannKind Corporation, are gaining traction among patients who prefer needle-free administration. Although currently used by a smaller proportion of the diabetic population, these alternatives pose a long-term threat to traditional pen needle usage by shifting treatment paradigms.
Environmental concerns and waste disposal challenges represent a growing issue for the North America Pen Needles Market. As millions of disposable pen needles are used daily across the region, the accumulation of medical sharps waste has become a pressing public health and environmental concern.
According to the U.S. Environmental Protection Agency (EPA), more than 3 billion used needles and syringes are discarded annually in the United States by contributing to biohazard waste streams that require specialized handling and disposal. Improperly disposed of needles pose risks to sanitation workers, healthcare personnel, and the general public, prompting stricter regulations on sharps management. Several states, including California and New York, have implemented stringent laws mandating the use of approved sharps disposal containers and designated drop-off locations. These environmental pressures are encouraging stakeholders to explore sustainable alternatives, such as reusable pen needles or biodegradable materials. While still in early stages, such innovations could redefine market dynamics and influence future purchasing behaviors, which is adding complexity to the traditional pen needle business model.
The Insulin Therapy segment was the largest by capturing a prominent share of the North America Pen Needles Market in 2024. One of the key drivers behind this segment’s dominance is the rising incidence of Type 1 and insulin-requiring Type 2 diabetes in the United States. According to the Centers for Disease Control and Prevention (CDC), over 37 million Americans live with diabetes, with more than 8.5 million requiring insulin therapy. The increasing adoption of pen-based delivery systems due to their ease of use, dosing accuracy, and portability further reinforces demand for compatible pen needles. Additionally, insulin pens are increasingly preferred over traditional vials and syringes, especially among elderly patients and caregivers. Data from the American Diabetes Association indicates that nearly 60% of insulin users in the U.S. now opt for pen devices, directly boosting needle sales.
The GLP-1 Therapy segment is lucratively growing with a CAGR of 19.3% in the coming years. A primary driver of this growth is the surge in obesity-related health conditions, which has prompted increased off-label and therapeutic use of GLP-1 analogs such as semaglutide and tirzepatide. According to the National Center for Health Statistics (NCHS), over 42% of U.S. adults were classified as obese in 2023, with pharmaceutical companies aggressively expanding indications for these drugs beyond diabetes into chronic weight control. Moreover, major pharmaceutical firms like Novo Nordisk and Eli Lilly have launched self-administered GLP-1 injectables, packaged with dedicated pen needles. A report by IQVIA noted that prescriptions for GLP-1-based medications grew by 65% in 2023, with nearly all formulations requiring pen injection devices.
The Standard Needle segment was the dominant shareholder of the North America Pen Needles Market in 2024. One of the main reasons for their continued dominance is cost sensitivity among consumers and healthcare providers, particularly in private insurance and out-of-pocket payment scenarios. Additionally, some patients who reuse needles or prefer manual injection methods tend to favor conventional models. Another contributing factor is the lack of universal mandates requiring safety-engineered needles, especially in certain states where regulatory enforcement remains lenient. While federal agencies like OSHA encourage safer practices, compliance varies across clinics and home care settings.
The Safety Needle segment is swiftly emerging with a CAGR of 12.7% throughout the forecast period. One of the primary drivers of this segment’s expansion is the increasing adoption of safety regulations in healthcare facilities. According to the Occupational Safety and Health Administration (OSHA), over 385,000 needle-stick injuries occur annually in U.S. hospitals, which is prompting widespread implementation of safer injection devices. Several states, including California and New York, have enacted laws mandating the use of safety-engineered needles in institutional settings.
Additionally, home healthcare providers and insurers are encouraging the use of safety needles to reduce risks among informal caregivers and family members. The Visiting Nurse Associations of America (VNAA) reported in 2023 that more than 70% of visiting nurses now recommend safety needles for diabetic patients receiving home care. These combined regulatory, clinical, and consumer-driven forces are accelerating the shift toward safer injection solutions, positioning this segment as the fastest-growing in the market.
The 4mm needle segment accounted for holding 42.1% of the North America Pen Needles Market share in 2024. One of the key drivers behind the dominance of 4mm needles is the growing body of clinical evidence supporting their efficacy and safety. According to a 2024 meta-analysis published in Diabetes Care, shorter needles (≤ 6mm) significantly reduce the risk of intramuscular insulin deposition, which can lead to erratic absorption and glycemic variability. Leading endocrinology associations, including the American Association of Clinical Endocrinologists (AACE), now recommend 4–6mm needles for most patients regardless of body mass index (BMI). Another major contributing factor is the expanding use of ultra-thin and micro-needles designed specifically for comfort and minimal tissue trauma. Manufacturers such as BD and Novo Nordisk have introduced 4mm Nano and FlexTouch-compatible models, which have gained popularity for their painless administration.
The 6mm needle segment is currently the fastest-growing in the North America Pen Needles Market, While slightly longer than the 4mm variant, the 6mm needle strikes an optimal balance between safety, effectiveness, and usability, making it increasingly favored across diverse patient demographics. One of the primary drivers of this growth is the recommendation by leading diabetes organizations for broader applicability across body types. According to guidelines issued by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), patients with higher BMI may benefit from slightly longer needles to ensure proper subcutaneous delivery without injection errors. Additionally, manufacturers are prioritizing 6mm needle integration into next-generation insulin pens, which includes smart and auto-injector models. For example, Sanofi and Lilly have optimized their latest pen devices for 6mm compatibility to enhance flow dynamics and reduce injection force.
The Retail segment dominated the North America Pen Needles Market with a prominent share in 2024. One of the primary reasons for retail’s dominance is the established presence of large pharmacy chains and national distributors such as CVS Health, Walgreens, and Walmart, which offer convenient access to diabetes supplies. According to the National Community Pharmacists Association (NCPA), over 90% of Americans live within five miles of a community pharmacy by ensuring widespread availability of essential products like pen needles. Additionally, private insurance plans and Medicare Part D often facilitate retail pharmacy reimbursement, making it easier for patients to obtain supplies without navigating complex procurement processes. The American Pharmacists Association (APhA) reported that pharmacies dispensed over 1.2 billion units of diabetes-related consumables in 2023, with pen needles constituting a significant portion.
The Non-Retail segment is swiftly emerging with an anticipated CAGR of 14.2% in the coming years. One of the key drivers of this segment’s rapid growth is the expansion of home healthcare services for elderly and mobility-impaired diabetic patients. According to the Visiting Nurse Associations of America (VNAA), home health utilization increased by 22% in 2023, with many agencies incorporating pen needles into standardized care packages for insulin-dependent individuals. Additionally, the rise of telemedicine and integrated diabetes care platforms has facilitated non-retail procurement channels, allowing patients to receive prescriptions and supplies remotely. Major insurers and Medicaid programs are also incentivizing bulk distribution through mail-order services to reduce administrative overhead and improve medication adherence.
The United States was the top performer in the North America Pen Needles Market by accounting for 82.3% of the share in 2024. One of the key drivers of this dominance is the high burden of diabetes, with over 37 million Americans affected as of 2024, according to the Centers for Disease Control and Prevention (CDC). Of these, more than 8.5 million require insulin therapy, largely administered via pen devices due to their convenience and dosing accuracy. The American Diabetes Association notes that nearly 60% of insulin users in the U.S. prefer pen-based delivery systems, which reinforces the need for compatible needles. Additionally, the U.S. market benefits from robust healthcare infrastructure, extensive insurance coverage for diabetes supplies, and continuous product innovation. Companies such as BD, Novo Nordisk, and Sanofi have established strong distribution networks by ensuring widespread availability of both standard and safety-engineered pen needles.
Canada was positioned second by holding 11.2% of the North America Pen Needles Market share in 2024, with its well-developed healthcare system, increasing diabetes prevalence, and proactive government policies promoting accessible diabetes care. According to Diabetes Canada, approximately 3.1 million Canadians live with diabetes with the number expected to rise sharply over the next decade, which is driving sustained demand for insulin delivery solutions.
Furthermore, Canadian healthcare providers are increasingly adopting modern insulin delivery systems, including smart pens and safety-engineered needles, aligning with global best practices. The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended the use of shorter needles to minimize complications, influencing prescribing patterns.
The competition in the North American Pen Needles Market is shaped by a combination of established medical device manufacturers, pharmaceutical companies with integrated delivery systems, and emerging players focusing on differentiated product offerings. The market is highly consolidated, with a few dominant firms controlling a significant portion of the supply chain through brand recognition, extensive distribution networks, and continuous product innovation. These companies leverage their expertise in diabetes care to develop needles that align with evolving clinical guidelines and patient preferences.
Amid growing demand for safer, more comfortable injection methods, competition is intensifying around technological differentiation. Manufacturers are investing in ultra-thin, micro-needles and safety-engineered models that minimize injury risks for both patients and caregivers. Additionally, the integration of pen needles with smart insulin delivery systems is becoming a key battleground for market share, as companies seek to offer holistic diabetes management solutions rather than standalone products.
Price sensitivity and reimbursement policies also play a crucial role in shaping competitive dynamics. While larger firms benefit from economies of scale and existing relationships with insurers and pharmacies, smaller innovators are attempting to carve out niches by introducing cost-effective yet high-performance alternatives.
Companies are leading the North American Pen Needles Market include
Top Players in the North America Pen Needles Market
Becton, Dickinson and Company (BD) is a global leader in medical technology and one of the most influential players in the North America Pen Needles Market. Known for its high-quality insulin delivery solutions, BD offers a wide range of pen needles designed for comfort, safety, and ease of use. The company’s commitment to innovation has led to the development of ultra-thin and short-length needles that cater to diverse patient needs.
Another major player is Novo Nordisk A/S, a Danish multinational pharmaceutical company with a strong presence in the U.S. and Canadian markets. While primarily known for its insulin products, Novo Nordisk also supplies compatible pen needles that are integrated into its FlexTouch and other pen systems. Its focus on seamless diabetes management solutions reinforces its role in shaping needle usage patterns.
Sanofi S.A. is also a key participant, offering pen needles tailored for use with its insulin pens like the SoloStar. Sanofi plays a vital role in ensuring that pen needles remain an integral part of insulin therapy across North America with a focus on patient-centric design and accessibility. Its strategic partnerships and product bundling strategies further enhance market penetration.
One of the primary strategies adopted by key players in the North America Pen Needles Market is product innovation focused on patient comfort and safety. Companies are continuously developing thinner, shorter needles with improved coatings and ergonomic designs to reduce injection pain and increase adherence among users. Another critical approach is strategic partnerships and collaborations with diabetes care providers, telemedicine platforms, and insurance companies, aimed at enhancing patient access to pen needles and improving reimbursement structures.
The leading firms are investing heavily in integrated diabetes ecosystems, where pen needles are bundled with smart insulin pens and digital health apps to offer comprehensive disease management solutions. These strategies collectively help manufacturers strengthen their competitive positioning and drive long-term market growth.
By Therapy
By Type
By Needle Length
By Mode of Purchase
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region